natgillin/translations-raw huggingface dataset:
In another aspect, the invention deals with, the use of an antibody, or one of its functional fragments or derivatives, and/or of a composition as above described for the preparation of a medicament intended to inhibit the growth and/or the proliferation of tumor cells. 
Pripravak iz patentnog zahtjeva 8 za upotrebu kao lijek. Antitijelo, ili njegov dvovalentni funkcionalni fragment, iz patentnih zahtjeva 1 do 7 ili pripravak iz patentnog zahtjeva 8 za upotrebu za inhibiciju rasta i/ili proliferacije tumorskih stanica.
The pharmaceutical composition of any one of claims 1 to 9 characterized in that the composition is a cream, comprising an oil phase and a water phase in admixture, the composition comprising about 4.5 to about 5.5 percent of the compound imiquimod, about 20 to about 30 percent isostearic acid, about 1.0 percent to about 2.1 percent benzyl alcohol, about 0.5 percent to about 2.5 percent cetyl alcohol, about 1 percent to about 3.5 percent stearyl alcohol, about 2 percent to about 4 percent petrolatum, about 3 percent to about 4 percent polysorbate 60, about 0.4 percent to about 0.8 percent of sorbitan monostearate, about 1 percent to about 3 percent of glycerin, about 0.18 to about 0.22 percent methylparaben, about 0.018 percent to about 0.022 percent propylparaben, about 0.0 to about 1.0 percent xanthan gum, and about 50 to about 55 percent purified water; all percentages being based upon the total weight of the composition. 
Farmaceutski pripravak iz bilo kojeg od patentnih zahtjeva 1 do 9, naznačen time, da je taj pripravak krema koja sadrži uljnu fazu i vodenu fazu u smjesi, pripravak sadrži oko 4,5 do oko 5,5 posto spoja imikvimoda, oko 20 do oko 30 posto izostearinske kiseline, oko 1,0 posto do oko 2,1 posto benzil alkohola, oko 0,5 posto do oko 2,5 posto cetil alkohola, oko 1 posto do oko 3,5 posto stearil alkohola, oko 2 posto do oko 4 posto petrolatuma, oko 3 posto do oko 4 posto polisorbata 60, oko 0,4 posto do oko 0,8 posto sorbitan monostearata, oko 1 posto do oko 3 posto glicerina, oko 0,18 do oko 0,22 posto metilparabena, oko 0,018 posto do oko 0,022 posto propilparabena, oko 0,0 do oko 1,0 posto xanthan gume te oko 50 do oko 55 posto pročišćene vode; svi postotci temelje se na ukupnoj težini pripravka.
An immunogenic pharmaceutical composition comprising a recombinant staphylococcal clumping factor A (ClfA) according to SEQ ID No. 1 or a sequence with at least 85%, preferably at least 95% sequence identity to the sequence of SEQ ID No. 1 or fragment thereof comprising at least amino acid residues 221 to 531 of the fibrinogen binding region (Region A), with at least one amino acid residue substitution or deletion at amino acid residue Ala254, Tyr256, Pro336, Tyr338, Ile387, Lys389, Glu526 and/or Val527 to result in a recombinant fibrinogen binding protein with reduced ability or lacking the ability to non-covalently bind fibrinogen which stimulates a greater immune response that the wild type ClfA protein, and a pharmaceutically acceptable adjuvant for use in the treatment or prophylaxis of Staphylococcal infections. 
17. Imunogeni farmaceutski pripravak koji sadrži rekombinantni stafilokokni faktor grudanja A (CIFA) prema SEQ ID No. 1 ili sekvenci s barem 85%, poželjno barem 95% identičnosti sekvence u odnosu na SEQ ID No. 1 ili njegov fragment koji obuhvaća barem aminokiselinske ostatke 221 do 531 fibrinogen vezujuće regije (Regija A), s barem jednom supstitucijom ili delecijom aminokiselinskog ostatka na aminokiselinskom ostatku Ala254, Tyr256, Pro336, Tyr338, 1le387, Lys389, Glu526 iili Val527 da se dobije rekombinantni fibrinogen vezujući protein sa smanjenom sposobnosti ili bez sposobnosti nekovalentnog vezanja fibrinogena što će stimulirati veći imuni odgovor od divljeg tipa CIfA proteina, i farmaceutski prikladan adjuvans za uporabu u liječenju ili prevenciji stafilokoknih infekcija.
A genic expression adenoviral hybrid vector according to claim 9, characterized in that element iv d) has the sequence SEQ ID NO: 5. 
Adenovirusni hibridni vektor sa genskom ekspresijom prema patentnom zahtjevu 1 ili 10, naznačen time što element iv. d) ima sekvencu SEQ ID No 5.
The switching system of claim 14, wherein the switching system comprises: 
Prekidački sustav u skladu s patentnim zahtjevom 14, naznačen time što prekidački sustav ima:
A combination of a) a compound of Formula Ia: 
Spoj, naznačen time, da ima formulu Ia:
The pharmaceutical composition according to (28), characterized in that the abnormal bone metabolism is osteoporosis, bone destruction accompanying rheumatoid arthritis or bone destruction accompanying cancer metastasis to bone. 
Farmaceutski pripravak za uporabu sukladno zahtjevu 17 ili 18, karakteriziran time što je abnormalni metabolizam kostiju osteoporoza, destrukcija kostiju koja prati reumatoidni artritis ili destrukcija kostiju koja prati metastaze raka u kostima.
A compound according to claim 25, wherein the disease, disorder, or medical condition is selected from the group consisting of: anxiety, pain, inflammation, sleep disorders, eating disorders, and movement disorders. 
Spoj prema zahtjevu 11, naznačen time da je bolest, poremećaj ili medicinsko stanje izabrano iz skupine koju čini tjeskoba, bol, upala, poremećaji spavanja, poremećaji prehrane i poremećaji kretanja.
selected from the group consisting of: wherein Ar is an optionally substituted aryl group; 
[image] gdje je Ar opcijski supstituirana aril grupa;
wherein, and Y is independently a group containing a first functional group (FG1), the FG1 being selected from the group consisting of: acetylene, azide, aldehyde, hydroxylamine, hydrazine, ketone, nitrobenzofurazan (NBD), dansyl, fluorescein, biotin, and Rhodamin, 
(I) pri čemu su P, i Y svaki nezavisno skupina koja sadržava prvu funkcionalnu skupinu (FG1), FG1 je odabran iz skupine koju čine: acetilen, azid, aldehid, hidroksilamin, hidrazin, keton, nitrobenzofurazan (NBD), danzil, fluorescein, biotin i Rodamin,
The tablet as defined in any one of claims 1-8, wherein the formulation exhibits dissolution properties such that an amount of the drug equivalent to at least 77% dissolves within 30 minutes, wherein the test result is established as an average of 6 tablets and wherein the dissolution test is performed in an aqueous media buffered to a pH in the range of 1 to 7.4 and controlled at 37° C (±1°C). 
Proces za proizvodnju tableta apiksabana kao što je definirano u jednom od patentnih zahtjeva 11 do 13, gdje tablete pokazuju takva svojstva topivosti da se količina lijeka ekvivalentna sa najmanje 77% otapa u 30 minuta, pri čemu se test topivosti izvodi u vodenom mediju puferiranom na pH opseg 1 do 7.4 i kontroliran je na 37° C.
CDRs 1, 2, and 3 of the second antibody H chain consist of SEQ ID NOs: 126-128, respectively; and 
(b7) mjesto vezanja antigena koje obuhvaća aminokiselinske sekvence H-lanca CDR-područja 1, 2 i 3 od SEQ ID NO: 126, 127 odnosno 128 (H-lanac CDR-područja od J327);
The reception apparatus according to one of claims 5 to 7, wherein the first aggregation level value is 2 and the second aggregation level value is 4 or 8. 
Naprava za prijem sukaldno jednom od zahtjeva od 5 do 7, naznačena time da je prva vrijednost razine agregacije 21 da je druga vrijednost razine agregacije 4 ili 6.
the glass valve retainer positioned in the neck of the container and having a radially inner surface, and the radially outer surface radially inward of the interior surface of the neck, 
HR P20170816 T1 gdje se vezivni materijal stavlja između unutarnje površine grla spremnika i prve radijalne vanjske površine prvog tijela ventila.
A combination according to claim 9, wherein the active compound (c) is selected from the group consisting of (i) PDE IV inhibitors and (b) cortiocosteroids. 
Kombinacija u skladu s patentnim zahtjevom 8, naznačena time, da je djelatni spoj (c) odabran iz skupine koju čine (a) B2-agonisti i (b) kortikosteroidi.
The composition according to the present invention may be provided in the form of a coating formulation, wherein the composition, may be dissolved or dispersed in a suitable medium, e.g. a medium selected from the group comprising water, alcohol ethers, alcohols, aliphatic hydrocarbons, esters, and mixtures thereof. 
Pripravak prema zahtjevu 17, naznačen time da je predviđen u obliku otopine ili disperzije u prikladnom tekućem HR P20160906 T1 mediju, poželjno mediju koji se bira iz skupine koju čine voda, alkoholni eteri, alkoholi, alifatski ugljikovodici, esteri, te njihove smjese.
Block buffer prepared by adding 1% BSA in PBS (No sucrose, neither NaN3added). 
- > Pufer za blokiranje je priređen dodavanjem 1% BSA u PBS-u (bez sukroze i NaN;).
The aqueous layer was made basic with ammonium hydroxide and extracted further with CH2Cl2 and concentration of the extracts gave a gum which was treated with HCl in ethanol to give an additional 0.9 g of intermediate 39. 
Vodeni sloj je napravljen baznim sa amonij hidroksidom i dodatno ckstrahiran sa CHC1 i koncentriranjem ekstrakta dobivena je guma koja je tretirana sa HCI u etanolu da bi se dobilo još 0.9 g Intermedijera 39.
The pharmaceutical composition of claim 1, wherein the interior solution and the exterior solution are selected from the group consisting of: Interior solution of 0.8% to 1.0% NaCl and 9% to 11% sucrose and exterior solution of 8 mM to 12 mM phosphate buffer (pH 6.5) and 9% to 11% sucrose, 
€) Unutarnje otopine iz 0,8-1,0% NaCI i 9-11% saharoze i vanjske otopine iz 8-12 mM fosfatnog pufera (pH 6,5) + 0,35-0,55% NaCl + 4-6% saharoze, d) Unutarnje otopine iz 1,6-2,0 mM NaCI i vanjske otopine iz 8-12 mM fosfatnog pufera (pH 6,5) + 0,8-1,0% NaCI.
In some embodiments, the polypeptide is less than 100 amino acids in length. Examples of a carrier peptide can include: 
Peptid nosač prema zahtjevu 1, naznačen time da polipeptid ima duljinu od manje od 100 amino kiselina.
The method according to claim 1, wherein the simulating is configured to operate such that no charging or reduced charging is incurred to the sender when a mobile message is not delivered to an existing recipient. 
Postupak prema bilo kojem od prethodnih zahtjeva, gdje je simulacija (250) podešena da funkcionira tako da ne dođe do naplate ili snižene naplate pošiljatelju kada se poruka ne pošalje postojećem primatelju.
The method according to claim 6, wherein, below a specific operating point of the reverse osmosis plant, the piston is moved by means of a hydraulic transmission. 
Postupak u skladu s patentnim zahtjevima 6 ili 7, naznačen time što se, ispod specifične radne točke postrojenja za povratnu osmozu, klip pomiče djelovanjem hidrauličnog prijenosa.
An oral dosage form according to claim 10, wherein said material is Eudragit™ L30D. 
Oralni oblik doziranja u skladu s patentnim zahtjevom 10, naznačen time što navedeni materijal je Eudragit"M L30D.
where each R3a, R3b, R3c, R3d, R3e and R3f is independently H, halo, hydroxyl, alkoxy, substituted alkoxy, acyl, acyloxy, unsubstituted or substituted alkyl, perhaloalkyl, unsubstituted or substituted alkenyl, unsubstituted or substituted alkynyl, unsubstituted or substituted aryl, unsubstituted or substituted heteroaryl, unsubstituted or substituted heterocyclyl, or is taken together with a geminal R3a-f and the carbon to which they are attached to form a carbonyl; and 
Spoj patentnog zahtjeva 1 gdje spoj ima formulu (VIb): [image] gdje svaki R3a, R3b, R3c, R3d, R3e i R3f je nezavisno H, halo, hidroksil, alkoksi, supstituiran alkoksi, acil, aciloksi, nesupstituiran ili supstituiran alkil, perhaloalkil, nesupstituiran ili supstituiran alkenil, nesupstituiran ili supstituiran alkinil, nesupstituiran ili supstituiran aril, nesupstituiran ili supstituiran heteroaril, nesupstituiran ili supstituiran heterociklil, ili je uzet zajedno sa geminalnim R3a-f i ugljikom za koji su vezani da formiraju karbonil; i
The present invention relates to a low cost, sustainable method and system for treating and maintaining bodies of water affected by bacteria and microalgae for low density recreational use. 
HR P20190425 T1 PATENTNI ZAHTJEVI 1. - Veliko umjetno vodeno tijelo na koje utječu bakterije i mikroalge 1 sustav za njegovu obradu i održavanje uz niske troškove, te obuhvaća:
The composition of claim 1, wherein the composition is for use in a method of treating or preventing a disease or condition selected from the group consisting of uveitis; cancer, such as breast cancer, lung cancer, liver cancer, colon cancer, or ovarian cancer; multiple sclerosis; arthritis, such as rheumatoid arthritis, osteoarthritis, psoriatic arthritis, or juvenile idiopathic arthritis; neuromyelitis optica (Devic's disease); ankylosing spondylitis; spondyloarthritis; psoriasis; systemic lupus erythematosus; inflammatory bowel disease, such as Crohn's disease or ulcerative colitis; celiac disease; asthma, such as allergic asthma or neutrophilic asthma; chronic obstructive pulmonary disease (COPD); scleritis; vasculitis; Behcet's disease; atherosclerosis; atopic dermatitis; emphysema; periodontitis; allergic rhinitis; and allograft rejection. 
Pripravak prema zahtjevu 1, naznačen time da je pripravak za upotrebu u postupku liječenja ili prevencije bolesti ili stanja koje se biraju iz skupine koja sadrži uveitis; rak, kao što je rak dojke, rak pluća, rak jetre, rak debelog crijeva, ili rak jajnika; multiple skleroza; artritis, kao što je reumatoidni artritis, osteoartritis, psorijazni artritis, ili juvenilni idiopatski artritis; neuromijelitis optika (Devicova bolest); ankilozirajući spondilitis; spondiloartritis; psorijaza; sistemski eritemski lupus; upalna bolest crijeva, kao što je Crohnova bolest ili ulcerativni kolitis; celijakija; astma, kao što je alergijska astma ili astma koja je posredovana neutrofilima; kronična opstruktivna plućna bolest (KOPB); skleritis; vaskulitis; Behcetova bolest; ateroskleroza; atopijski dermatitis; emfizem; periodontitis; alergijski rinitis; te odbacivanje alografta.
wherein R1 at each occurrence is independently selected from H, halogen, or the groups selected from (C1-C12)alkyl, haloalkyl, cycloalkyl, alkylthio or the group (OSO2) alkyl, wherein each of these groups may be further substituted by suitable substituents selected from hydroxyl, oxo, halo, thio, nitro, amino, alkyl, alkoxy, haloalkyl and haloalkoxy groups; 
No zi gdje je R' prilikom svakog pojavljivanja, neovisno odabran od H, halogena ili skupina koje su odabrane od sljedećih: (C;-Cr)alkil, haloalkil, cikloalkil, alkiltio ili skupine (OSO>)alkil, pri čemu se svaka od navedenih skupina prema potrebi može dalje supstituirati s prikladnim supstituentima odabranima od sljedećih skupina: hidroksil, okso, halo, tio, nitro, amino, alkil, alkoksi, haloalkil 1 haloalkoksi;
The method according to claim 13, wherein the distribution of said adhesive is a distribution of powder of adhesive, or of spots of adhesive of the hot-melt type, having a diameter substantially from 2 0.1 to 2.0 mm and a density from 50 to 600 spots/cm2. 
Postupak u skladu s patentnim zahtjevom 13, naznačen time, da se navedeno ljepilo nanosi u obliku praškastog ljepila ili se nanose točkice taljivog ljepila promjera u biti 0,1 do 2,0 mm uz gustoću točkica od 50 do 600 točkica na cm".
The process according to any one of claims 1 to 7, wherein the carboxylic groups of the at least one modified polysaccharide are at least partly neutralized by adding to the aqueous mineral pigment material suspension prior or during the grinding step d) one or more polyvalent cations, in situ formed, by adding an acid, preferably H3PO4, or acidic reacting salt such as Na2HP04, preferably CaHPO4. 
Postupak prema bilo kojem od zahtjeva 1 do 7, gdje su karboksilne skupine barem jednog modificiranog polisaharida barem djelomično neutralizirane tako da se vodenoj suspenziji mineralnog pigmentnog materijala dodaje prije ili za vrijeme koraka usitnjavanja d) jedan ili više polivalentnih kationa, in situ formiranih, putem dodavanja kiseline, poželjno H3PO,, ili kiselo reaktivne soli kao što je Na»HPO,, poželjno CaHPO..
The reaction is stirred for about 2 hours and concentrated. 
Reakcijsku smjesu miješa se otprilike 2 sata, te koncentrira.
A combination comprising a therapeutically effective amount a compound according to any one of paragraphs 1 to 9 and one or more further drug substances, said further drug substance being useful in the treatment of neoplastic diseases or immune system disorders. 
Kombinacija, naznačena time, da sadrži terapeutski učinkovitu količinu spoja prema bilo kojem od zahtjeva 1 do 3, te jednu ili više drugih ljekovitih tvari, pri čemu je spomenuta druga ljekovita tvar korisna u liječenju neoplastičnih bolesti i poremećaja imunološkog sustava.
A nozzle for applying a lining material onto an inner surface of a pipe to create a lining in the pipe, comprising: 
Mlaznica (101) za nanošenje materijala za unutarnje oblaganje na unutarnju površinu cijevi kako bi nastala unutarnja obloga u cijevi, sadrži:
Preferred embodiments include soluble fragment or domain of the FGF receptor 2 isotype or variant IIIc encoded by a polynucleotide having the sequence of SEQ ID NO: 3, and/or having the amino acid sequence of SEQ ID NO: 4 or a sequence with at least 95%, 97%, 98%, or 99% identity with the SEQ ID NO: 4. 
Modificirana fuzija između topivog FGF receptora i Fc u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačena time što topiva domena FGF receptora ima slijed kao što je iznijet u SEQ ID NO:4, ili slijed koji je u najmanju ruku 95% identičan sa SEQ ID NO:4.
It was therefore entirely by surprise, and in contrast to the expectation based on common additives used to increase pH, that the Applicant identified that 2-((1-methylpropyl)amino)ethanol can be used as an additive in an aqueous suspension and having a pH of between 8.5 and 11 and containing from 25 to 62 vol. % of at least one calcium carbonate-comprising material, to increase the suspension pH by at least 0.3 pH units, while maintaining the suspension conductivity to within 100 uS/cm/pH unit. Therefore, a first aspect of the present invention refers to the use of 2-((1-methylpropyl)amino)ethanol 
U poraba 2-((1-metilpropil)aminojetanola kao aditiva u vodenoj otopini, sadrži 25 do 62 vol.% na temelju ukupnog volumena otopine, barem jednog materijala s kalcijevim karbonatom i ima pH između 8,5 i 11, za povećanje pH otopine za najmanje 0,3 pH jedinice, pri čemu promjena vodljivosti otopine nije veća od 100 uS/cm po jedinici pH, karakterizirana na način da je navedeni 2-((1-metilpropil)amino)etanol dodan u navedenu otopinu u količini od 500 do 1500 mg, po litri vodene faze navedene otopine.
The results from the analyses are presented in Table 27. 
AE912-hGH-AE144 ili AE912-hGH-AE288, koje su prikazane u Tablici 36.
The blender system of claim 7 wherein the agitating means comprises a mixer base and one or more blades rotatably coupled to the mixer base. 
Sustav mješalice prema zahtjevu 14, naznačen time, što dio za miješanje (108) uključuje bazu (110) miksera i jednu ili više oštrica koje su spojene na bazu (110) miksera na način da se mogu okretati.
Use of a compound according to any one of claims 1 to 3 to manufacture a medicament for use in the treatment of conditions or disorders mediated by S1P1 receptors. Use according to claim 7, wherein the condition or disorder multiple sclerosis, autoimmune diseases, chronic inflammatory disorders, asthma, inflammatory neuropathies, arthritis, transplantation, Crohn's disease, ulcerative colitis, lupus erythematosis, psoriasis, ischemia-reperfusion injury, solid tumours, and tumour metastasis, diseases associated with angiogenesis, vascular diseases, pain conditions, acute viral diseases, inflammatory bowel conditions, insulin and non-insulin dependent diabetes. 
Upotreba spoja u skladu s patentnim zahtjevom 1, naznačena time što je navedeni spoj namijenjen proizvodnji medikamenta namijenjenog upotrebi u liječenju stanja ili poremećaja povezanih s receptorima S1P1, gdje je stanje ili poremećaj multipla skleroza, autoimune bolesti, kronični upalni poremećaji, astma, upalne neuropatije, artritis, presađivanje, Crohnova bolest, ulcerozni kolitis, eritematozni lupus, psorijaza, ishemijsko-reperfuzijska ozljeda, čvrsti tumori i tumorske metastaze, bolesti povezane s angiogenezom, vaskularne bolesti, bolna stanja, akutne virusne bolesti, upalna crijevna stanja, dijabetes ovisan o inzulinu i dijabetes neovisan o inzulinu.
no ring double bonds), unsaturated (i.e., containing ring double bonds) or a combination thereof. 
bez dvostrukih veza), nezasićen (t.j. sadrži dvostruke veze u prstenu) ili kombinacija navedenog.
The aqueous pharmaceutical suspension according to claim 4, comprising, by weight/volume (g/100 mL), 0.60% of fexofenadine zwitterionic dihydrate Form I, 2.5% of propylene glycol, 0.15% of edentate disodium, 0.034% of propylparaben 0.017% of butylparaben, 0.35% of xanthan gum, 0.05% of Poloxamer 407, 1.25% of sodium phosphate dibasic heptahydrate, 0.75% of sodium phosphate monobasic monohydrate, 20% of sucrose, and 10% of sorbitol solution. 
Vodena farmaceutska, suspenzija u skladu s patentnim zahtjevom 7, naznačena time što sadrži, težinski/volumno (£/100 ml), otprilike 0,60 % dvojnoionskog dihidratnog Oblika I feksofenadina, otprilike 2,5 % propilen-glikola, otprilike 0,15 % dinatrijevog edetata, otprilike 0,034 % propilparabena, otprilike 0,017 % butilparabena, otprilike 0,35 % ksantanske gume, otprilike 0,05 % Poloksamera 407, otprilike 1,25 % dvobaznog natrijevog fosfata heptahidrata, otprilike 0,75 % jednobaznog natrijevog fosfata monohidrata, otprilike 20 % saharoze, te otprilike 10 % otopina sorbitola.
The composition for use of claim 6, wherein at least 30% of the interferon alpha-2b and L-methionine in the composition to be administered are present in the entrapped oil-in-water emulsion. 
10. Pripravak za uporabu u skladu s patentnim zahtjevom 6, naznačen time, da se najmanje 30 % interferona alfa-2b i
The pharmaceutical composition of claim 8, wherein the pharmaceutical composition is to be administered intraperitoneally, intramuscularly, intravenously, intranasally, subcutaneously, intradermally, or intrathecally. 
Farmaceutski sastav prema patentnom zahtjevu 3, gdje se farmaceutski sastav primjenjuje intraperitonealno, intramuskularno, intravenozno, intranazalno, potkožno, intradermalno ili intratekalno.
A system according to any one of the preceding claims, wherein the user receiver (R) is provided with a digital signal processor, arranged to distinguish particular emergency service signals (S) from interference signals. 
Sustav prema zahtjevu 7, pri čemu je spomenuti korisnički prijemnik (R) opremljen drugim pojasnim propusnim filtrom (6) za ponovno filtriranje signala koje je obradio sklop za miješanje.
In some embodiments of the process, the hydrogen chloride exiting the reaction zone contains 1,1,3-trichloropropene and/or carbon tetrachloride and 1,1,3-trichloropropene and/or carbon tetrachloride are recycled into the reaction zone via the condensing zone. 
Postupak prema zahtjevu 1, gdje je klorovodik nusproizvod postupka te se uklanja iz reakcijske zone kroz zonu odvajanja i zonu kondenzacije, i dalje gdje klorovodik koji izlazi iz reakcijske zone sadrži 1,1,3-trikloropropen ili ugljik tetraklorid ili oba 1,1,3-trikloropropen i ugljik tetraklorid i 1,1,3-trikloropropen ili ugljik tetraklorid ili oba 1,1,3-trikloropropen i ugljik tetraklorid se recikliraju u reakcijsku zonu putem zone kondenzacije.
Even more preferred, L1 is selected from the group consisting of wherein R has the meaning as indicated above. 
R', R*, R* neovisno odabrani iz skupine koja se sastoji od sljedećih: H; T;
The tablet of claim 1 or 2 which comprises 27.5 ± 1.4 mg of rilpivirine HCl. 
Tableta zahtjeva 1 ili 2 koja sadrži 27.5 + 1.4 mg rilpivirin HCI.
An antibody that binds CDR19, said antibody comprising a light chain comprising SEQ ID NO: 106, and a heavy chain comprising SEQ ID NO: 87. 
Antitijelo prema zahtjevu 1, naznačeno time da navedeni teški lanac sadrži SEQ ID NO: 40 i navedena sekvenca lakog lanca sadrži SEQ ID NO: 58.